Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
K Su, L Shi, T Sheng, X Yan, L Lin, C Meng… - Nature …, 2024 - nature.com
Fully targeted mRNA therapeutics necessitate simultaneous organ-specific accumulation
and effective translation. Despite some progress, delivery systems are still unable to fully …
and effective translation. Despite some progress, delivery systems are still unable to fully …
[HTML][HTML] Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery
J Wang, Y Ding, K Chong, M Cui, Z Cao, C Tang… - Vaccines, 2024 - mdpi.com
Introduction: The advent of lipid nanoparticles (LNPs) as a delivery platform for mRNA
therapeutics has revolutionized the biomedical field, particularly in treating infectious …
therapeutics has revolutionized the biomedical field, particularly in treating infectious …
Lipid nanoparticles-based RNA therapies for breast cancer treatment
L Serpico, Y Zhu, RF Maia, S Sumedha… - Drug Delivery and …, 2024 - Springer
Breast cancer (BC) prevails as a major burden on global healthcare, being the most
prevalent form of cancer among women. BC is a complex and heterogeneous disease, and …
prevalent form of cancer among women. BC is a complex and heterogeneous disease, and …
RNA delivery systems
SN Bhatia, JE Dahlman - Proceedings of the National …, 2024 - National Acad Sciences
Between December 2020 and December 2021, COVID-19 vaccines prevented over 14
million deaths (1). Two of these vaccines were lipid nanoparticles (LNPs) formulated to carry …
million deaths (1). Two of these vaccines were lipid nanoparticles (LNPs) formulated to carry …
Organ-and Cell-Selective Delivery of mRNA In Vivo Using Guanidinylated Serinol Charge-Altering Releasable Transporters
Selective RNA delivery is required for the broad implementation of RNA clinical applications,
including prophylactic and therapeutic vaccinations, immunotherapies for cancer, and …
including prophylactic and therapeutic vaccinations, immunotherapies for cancer, and …
Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads
Gene editing technologies have the potential to correct genetic disorders by modifying,
inserting, or deleting specific DNA sequences or genes, paving the way for a new class of …
inserting, or deleting specific DNA sequences or genes, paving the way for a new class of …
A Chemoinformatic-Guided Synthesis of a Spleen-Expressing mRNA Lipid Nanoparticle Platform
mRNA lipid nanoparticles (LNPs) are a powerful technology that are actively being
investigated for their ability to prevent, treat, and study disease. However, a major limitation …
investigated for their ability to prevent, treat, and study disease. However, a major limitation …
[HTML][HTML] Nanoparticles for RNA Therapeutics: RNA delivery systems
SN Bhatia, JE Dahlman - Proceedings of the National Academy of …, 2024 - ncbi.nlm.nih.gov
Between December 2020 and December 2021, COVID-19 vaccines prevented over 14
million deaths (1). Two of these vaccines were lipid nanoparticles (LNPs) formulated to carry …
million deaths (1). Two of these vaccines were lipid nanoparticles (LNPs) formulated to carry …
Pharmaceutical Strategies for Optimized mRNA Expression
Y Shi, J Mao, S Wang, S Ma, L Luo, J You - Biomaterials, 2024 - Elsevier
Messenger RNA (mRNA)-based immunotherapies and protein in situ production therapies
hold great promise for addressing theoretically all the diseases characterized by aberrant …
hold great promise for addressing theoretically all the diseases characterized by aberrant …
Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy
S Soroudi, MR Jaafari, L Arabi - Journal of Controlled Release, 2024 - Elsevier
Cardiovascular diseases (CVDs) are the leading cause of global mortality among non-
communicable diseases. Current cardiac regeneration treatments have limitations and may …
communicable diseases. Current cardiac regeneration treatments have limitations and may …